A Decade-long Battle: Successful Stereotactic Radiotherapy for a Delayed Lung Metastasis from Endometrial Cancer

Area of Science:

• Gynecologic Oncology
• Radiation Oncology
• Pulmonary Medicine

Background:

• Solitary lung metastases from endometrial carcinoma are rare, especially over 10 years post-resection.
• Limited data exists on stereotactic ablative radiotherapy (SABR) for these late-occurring metastases.

Purpose of the Study:

• To evaluate the safety and efficacy of SABR for a solitary lung metastasis of endometrial carcinoma presenting more than 10 years after initial treatment.
• To assess the feasibility of SABR in a patient with comorbidities precluding surgical intervention.

Main Methods:

• A case report of a 76-year-old woman with a history of endometrial carcinoma 13 years prior.
• Diagnosis of a solitary lung metastasis confirmed as originating from endometrial carcinoma.
• Treatment with stereotactic ablative radiotherapy (SABR) due to surgical ineligibility.

Main Results:

• The patient tolerated SABR well, with no reported adverse events during treatment or up to 2 years post-SABR.
• The treatment was effective in managing the solitary lung metastasis.

Conclusions:

• Stereotactic ablative radiotherapy (SABR) is a potentially safe and effective treatment option for late-occurring solitary lung metastases from endometrial carcinoma.
• SABR should be considered for patients with endometrial cancer recurrence presenting as isolated lung metastases, particularly when surgery is not an option.